Patent application number | Description | Published |
20100221317 | DYNAMIN MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS - This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | 09-02-2010 |
20100272709 | CATHEPSIN L MEDIATED DISEASES AND ASSOCIATED METHODS AND PRODUCTS - This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer. | 10-28-2010 |
20100297139 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES - The present invention is directed to methods of treating proteinuric diseases by the administration of avĪ²3 integrin inhibitors. | 11-25-2010 |
20110212083 | ROLE OF SOLUBLE UPAR IN THE PATHOGENESIS OF PROTEINURIC KIDNEY DISEASE - Compositions which specifically block urokinase receptor (uPAR) in podocytes; compositions which modulate or block soluble urokinase receptor (suPAR); compositions which modulate pathways in which uPAR is associated with, protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions. | 09-01-2011 |
20110236397 | LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF RENAL DISEASE - Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions. | 09-29-2011 |
20120195876 | NOVEL ROLE OF ALPHA-GALACTOSIDASE ACTIVITY AS A BIOMARKER IN KIDNEY DISEASE - Biomarkers for diagnosis and differentiation between stages of kidney diseases. Methods of treatments and identification of novel therapies are provided. | 08-02-2012 |
20120213775 | TREATMENT OF RENAL DISEASES - Compositions for the treatment of renal diseases and disorders utilize agents which inhibit alphaV integrin molecules in vivo. Methods of treatment include use of these agents in the prevention and treatment of proteinuria, progressive glomerular disease and glomerular disease amongst others. | 08-23-2012 |
20120219542 | PODOCYTE PH MODULATION AND USES THEREOF - Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. Biomarkers for predisposition to kidney diseases and diagnosis are identified. | 08-30-2012 |
20120251527 | PODOCYTE SPECIFIC ASSAYS AND USES THEREOF - Compositions are directed to the treatment of kidney diseases in a cell-specific manner. Methods of treating kidney diseases comprise the use of the compositions. Assays for identification of further compounds are provided. | 10-04-2012 |